REATA PHARMACEUTICALS
biopharmaceutical company
The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 2 of its records are shown together here.
These two are not added together. An organisation lobbying for itself reports its own spending, and the firms it retains report what they were paid; the rules ask the first to include the second, but filings do not always do so and a filing gives no way to tell. Each is shown as reported.
Reported lobbying by year
Filings
| Filing | Filed by | Amount |
|---|---|---|
|
2nd Quarter - Termination (No Activity) 2nd Quarter 2013
|
REATA PHARMACEUTICALS | — reported |
|
1st Quarter - Report (No Activity) 1st Quarter 2013
|
REATA PHARMACEUTICALS | — reported |
|
4th Quarter - Report (No Activity) 4th Quarter 2012
|
REATA PHARMACEUTICALS | — reported |
|
4th Quarter - Termination 4th Quarter 2012
|
UPSTREAM CONSULTING | $20,000 reported |
|
3rd Quarter - Report 3rd Quarter 2012
|
REATA PHARMACEUTICALS | $65,000 reported |
|
Registration 3rd Quarter 2012
|
REATA PHARMACEUTICALS | — reported |
|
3rd Quarter - Report 3rd Quarter 2012
|
UPSTREAM CONSULTING | $20,000 reported |
|
Registration 3rd Quarter 2012
|
UPSTREAM CONSULTING | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| REATA PHARMACEUTICALS In-house | 4 | $65,000 |
| UPSTREAM CONSULTING | 2 | $40,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 5 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.